Statin Therapy Induces Gut Leakage and Neuromuscular Disjunction in Patients With Chronic Heart Failure
暂无分享,去创建一个
[1] R. Qaisar,et al. Plasma Galectin-3 and H-FABP correlate with poor physical performance in patients with congestive heart failure , 2023, Experimental biology and medicine.
[2] R. Qaisar,et al. Plasma zonulin correlates with cardiac dysfunction and poor physical performance in patients with chronic heart failure. , 2022, Life sciences.
[3] M. J. Pons,et al. Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients , 2022, Frontiers in Cellular and Infection Microbiology.
[4] J. Killian,et al. Activities of Daily Living and Outcomes in Patients with Advanced Heart Failure. , 2022, The American journal of medicine.
[5] R. Qaisar,et al. Elevated plasma zonulin and CAF22 are correlated with sarcopenia and functional dependency at various stages of Alzheimer’s diseases , 2022, Neuroscience Research.
[6] B. Ding,et al. Intestinal Permeability Associated with the Loss of Skeletal Muscle Strength in Middle-Aged and Older Adults in Rural Area of Beijing, China , 2022, Healthcare.
[7] R. Qaisar,et al. A multistrain probiotic reduces sarcopenia by modulating Wnt signaling biomarkers in patients with chronic heart failure. , 2022, Journal of Cardiology.
[8] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[9] Weiqing Wang,et al. The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function , 2022, Frontiers in Microbiology.
[10] R. Halwani,et al. SARS‐CoV‐2 infection induces soluble platelet activation markers and PAI‐1 in the early moderate stage of COVID‐19 , 2022, bioRxiv.
[11] M. D’Amato,et al. Intestinal Barrier and Permeability in Health, Obesity and NAFLD , 2021, Biomedicines.
[12] R. Qaisar,et al. Intestinal permeability marker zonulin as a predictor of sarcopenia in chronic obstructive pulmonary disease. , 2021, Respiratory medicine.
[13] R. Qaisar,et al. Prediction of Sarcopenia Using Multiple Biomarkers of Neuromuscular Junction Degeneration in Chronic Obstructive Pulmonary Disease , 2021, Journal of personalized medicine.
[14] Jonathan P. Jacobs,et al. Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome , 2021, Frontiers in Endocrinology.
[15] M. Bona,et al. Intestinal barrier function in obesity with or without metabolic syndrome: a systematic review protocol , 2021, BMJ Open.
[16] Lin Bai,et al. Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles , 2021, Cell Death & Disease.
[17] Amber Price,et al. Dysbiosis and Intestinal Barrier Dysfunction in Pediatric Congenital Heart Disease Is Exacerbated Following Cardiopulmonary Bypass , 2021, JACC. Basic to translational science.
[18] C. Lewis,et al. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. , 2020, American journal of physiology. Heart and circulatory physiology.
[19] M. Jackson,et al. Neuron‐specific deletion of CuZnSOD leads to an advanced sarcopenic phenotype in older mice , 2020, Aging cell.
[20] J. Springer,et al. Muscle Wasting and Sarcopenia in Heart Failure—The Current State of Science , 2020, International journal of molecular sciences.
[21] R. Qaisar,et al. Plasma CAF22 Levels as a Useful Predictor of Muscle Health in Patients with Chronic Obstructive Pulmonary Disease , 2020, Biology.
[22] C. Deaton,et al. Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction , 2020, ESC heart failure.
[23] M. Pirmohamed,et al. Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components , 2019, Journal of clinical medicine.
[24] D. Tilley,et al. Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. , 2019, Biochimica et biophysica acta. Molecular basis of disease.
[25] Heetae Lee,et al. Alterations in Gut Microbiota by Statin Therapy and Possible Intermediate Effects on Hyperglycemia and Hyperlipidemia , 2019, Front. Microbiol..
[26] H. Westerblad,et al. A Mechanism for Statin-Induced Susceptibility to Myopathy , 2019, JACC. Basic to translational science.
[27] M. Camilleri. Leaky gut: mechanisms, measurement and clinical implications in humans , 2019, Gut.
[28] M. Harris-Love,et al. The Influence of Upper and Lower Extremity Strength on Performance-Based Sarcopenia Assessment Tests , 2018, Journal of functional morphology and kinesiology.
[29] Davor Milicic,et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.
[30] Benjamin Geiger,et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection , 2018, Science.
[31] G. Fonarow,et al. Statins and the Prevention of Heart Disease. , 2017, JAMA cardiology.
[32] D. Gutekunst,et al. Isokinetic Torque Timing Parameters and Ceramides as Markers of Muscle Dysfunction in Systolic Heart Failure. , 2016, Journal of cardiac failure.
[33] R. Aquilani,et al. Pathogenic Gut Flora in Patients With Chronic Heart Failure. , 2016, JACC. Heart failure.
[34] S. Anker,et al. Detection of muscle wasting in patients with chronic heart failure using C‐terminal agrin fragment: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) , 2015, European journal of heart failure.
[35] Jibin Zhou,et al. Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. , 2014, Journal of the American College of Cardiology.
[36] M. T. Ryan,et al. Supplemental Digital Content , 2013 .
[37] R. Saxena,et al. Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients , 2013, Thrombosis and Haemostasis.
[38] N. Maragakis,et al. Selected statins produce rapid spinal motor neuron loss in vitro , 2012, BMC Musculoskeletal Disorders.
[39] J. Auwerx,et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. , 2012, European heart journal.
[40] M. Francolini,et al. Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction , 2010, Journal of Cell Science.
[41] S. Lines,et al. Dipstick test for myoglobinuria , 2008, BMJ : British Medical Journal.
[42] P. Sonderegger,et al. Neurotrypsin cleaves agrin locally at the synapse , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[43] P. Sirvent,et al. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. , 2005, Biochemical and biophysical research communications.
[44] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[45] R. Qaisar,et al. Circulating Biomarkers of Handgrip Strength and Lung Function in Chronic Obstructive Pulmonary Disease , 2020 .
[46] K. Glas,et al. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.